Fifty 1 Labs Inc. Signs Letter of Intent to Acquire BioSpark AI Technologies Inc.
Fifty 1 Labs (OTC: FITY) has signed a Letter of Intent to acquire BioSpark AI Technologies, a Vancouver-based AI innovator specializing in clinical data analysis. The acquisition terms include 25 million common shares contingent upon BioSpark achieving a revenue-based valuation milestone of US$25 million.
The deal encompasses BioSpark's proprietary large language model ensemble technology and key intellectual property, including US Patent Application Publication No. US 20250029734 A1. The companies' previous collaboration has already yielded significant results, including the identification of over 2,000 real-world treatment pathways in drug repurposing initiatives.
This strategic acquisition aims to strengthen Fifty 1 Labs' position in the AI-healthcare market, focusing on drug discovery, personalized medicine, and healthcare optimization.
Fifty 1 Labs (OTC: FITY) ha firmato una Lettera di Intenti per acquisire BioSpark AI Technologies, un innovatore nell'AI con sede a Vancouver specializzato nell'analisi di dati clinici. Le condizioni dell'acquisizione includono 25 milioni di azioni comuni, condizionate al raggiungimento di un traguardo di valutazione basato sui ricavi di 25 milioni di dollari USA.
L'accordo comprende la tecnologia proprietaria di ensemble di modelli linguistici di BioSpark e la relativa proprietà intellettuale, inclusa la pubblicazione della Domanda di Brevetto degli Stati Uniti n. US 20250029734 A1. La collaborazione pregressa tra le aziende ha già prodotto risultati significativi, tra cui l'identificazione di più di 2.000 percorsi di trattamento reali in iniziative di riposizionamento di farmaci.
Questa acquisizione strategica mira a rafforzare la posizione di Fifty 1 Labs nel mercato AI-salute, concentrandosi su scoperta di farmaci, medicina personalizzata e ottimizzazione dell'assistenza sanitaria.
Fifty 1 Labs (OTC: FITY) ha firmado una Carta de Intención para adquirir BioSpark AI Technologies, una innovadora de IA con sede en Vancouver que se especializa en análisis de datos clínicos. Los términos de la adquisición incluyen 25 millones de acciones comunes, condicionadas a que BioSpark alcance un hito de valoración basado en ingresos de US$25 millones.
El acuerdo abarca la tecnología propietaria de conjuntos de modelos de lenguaje grande de BioSpark y la propiedad intelectual clave, incluida la Publicación de la Solicitud de Patente de EE. UU. No. US 20250029734 A1. La colaboración previa entre las empresas ya ha producido resultados significativos, incluido el identificar más de 2.000 rutas de tratamiento en el mundo real en iniciativas de reutilización de fármacos.
Esta adquisición estratégica busca fortalecer la posición de Fifty 1 Labs en el mercado de IA para salud, centrándose en descubrimiento de fármacos, medicina personalizada y optimización de la atención médica.
Fifty 1 Labs (OTC: FITY)는 BioSpark AI Technologies를 인수하기 위한 의향서에 서명했으며, 밴쿠버에 본사를 둔 임상 데이터 분석을 전문으로 하는 AI 혁신기업입니다. 인수 조건에는 BioSpark가 매출 기준 평가 마일스톤을 2,500만 달러 달성할 경우 2,500만 주의 보통주가 포함됩니다.
거래에는 BioSpark의 독자적 대형 언어 모델 앙상블 기술과 주요 지적 재산이 포함되며, 미국 특허 출원 공개번호 US 20250029734 A1도 포함됩니다. 양사의 이전 협업은 이미 중요한 결과를 낳았으며, 약물 재배치 이니셔티브에서 실제 세계 치료 경로를 2,000개 이상 식별하는 성과가 있습니다.
이 전략적 인수는 Fifty 1 Labs의 AI-헬스케어 시장에서의 위치를 강화하고, 약물 발견, 개인화 의학 및 건강 관리 최적화에 초점을 맞출 예정입니다.
Fifty 1 Labs (OTC: FITY) a signé une lettre d'intention pour acquérir BioSpark AI Technologies, un innovateur en IA basé à Vancouver, spécialisé dans l'analyse de données cliniques. Les conditions de l'acquisition prévoient 25 millions d'actions ordinaires, conditionnées à l'atteinte d'un cap basé sur la valeur des revenus de 25 millions de dollars US.
L'accord comprend la technologie propriétaire d'ensemble de grands modèles de langage de BioSpark et la propriété intellectuelle clé, y compris la publication de la demande de brevet américain n° US 20250029734 A1. La collaboration préalable entre les sociétés a déjà donné des résultats significatifs, notamment l'identification de plus de 2 000 itinéraires de traitement dans le monde réel dans le cadre d'initiatives de repositionnement des médicaments.
Cette acquisition stratégique vise à renforcer la position de Fifty 1 Labs sur le marché IA-santé, en mettant l'accent sur la découverte de médicaments, la médecine personnalisée et l'optimisation des soins de santé.
Fifty 1 Labs (OTC: FITY) hat eine Absichtserklärung unterzeichnet, um BioSpark AI Technologies, einen in Vancouver ansässigen AI-Innovator, zu übernehmen, der sich auf die Analyse klinischer Daten spezialisiert hat. Die Übernahmebedingungen umfassen 25 Millionen Stammaktien, vorbehaltlich der Erreichung eines umsatzbasierten Bewertungsmeile mit einem Wert von US$25 Millionen.
Der Deal umfasst die proprietäre Ensemble-Technologie von BioSpark für große Sprachmodelle und wichtiges geistiges Eigentum, einschließlich der US-Patentanmeldungsveröffentlichung Nr. US 20250029734 A1. Die frühere Zusammenarbeit der Unternehmen hat bereits signifikante Ergebnisse geliefert, darunter die Identifizierung von über 2.000 realen Behandlungswegen in Initiativen zur Wiedernutzung von Medikamenten.
Diese strategische Übernahme zielt darauf ab, die Position von Fifty 1 Labs im AI-Gesundheitsmarkt zu stärken, mit Fokus auf Arzneimittelforschung, personalisierte Medizin und Gesundheitsoptimierung.
Fifty 1 Labs (OTC: FITY) وقّعت على رسالة نوايا لشراء BioSpark AI Technologies، وهي مبتكرة ذكاء اصطناعي مقرها في فانكوفر ومتخصصة في تحليل البيانات السريرية. تشمل شروط الصفقة 25 مليون سهم عادي، وتبعاً لتحقيق معلم تقييم قائم على الإيرادات بقيمة 25 مليون دولار أمريكي.
التDeal يشمل التقنية الملكية للنموذج اللغوي الكبير من BioSpark وحقوقها الفكرية الأساسية، بما في ذلك نشر طلب براءة اختراع أمريكي رقم US 20250029734 A1. التعاون السابق بين الشركتين أفضى إلى نتائج مهمة، من بينها تحديد أكثر من 2,000 مسار علاج في العالم الواقعي في مبادرات إعادة تعيين الأدوية.
تهدف هذه الاستحواذية الاستراتيجية إلى تعزيز موقع Fifty 1 Labs في سوق الذكاء الاصطناعي الصحي، مع تركيز على اكتشاف الأدوية والطب الشخصي وتحسين رعاية الصحة.
Fifty 1 Labs (OTC: FITY) 已签署一份意向书，拟收购 BioSpark AI Technologies，这是一家总部位于温哥华的 AI 创新公司，专注于临床数据分析。收购条款包括在 BioSpark 实现基于收入的估值里程碑达到 2500 万美元时，提供 2500 万股普通股。
交易涵盖 BioSpark 的专有大型语言模型集合技术及核心知识产权，其中包括美国专利申请公开号 US 20250029734 A1。双方此前的合作已经产生显著成果，包括在药物再定位倡议中识别出 超过 2000 个现实世界治疗路径。
此次战略收购旨在增强 Fifty 1 Labs 在 AI-健康市场的地位，聚焦药物发现、个性化医疗和医疗保健优化。
- Acquisition includes valuable intellectual property and proprietary LLM ensemble technology
- Previous collaboration demonstrated success with 2,000+ treatment pathways identified
- Payment structure is milestone-based, reducing upfront risk
- Key BioSpark employees will be retained to ensure operational continuity
- Positions company to target multi-billion-dollar markets in drug repurposing and personalized medicine
- Potential share dilution with 25 million new common shares
- Acquisition closing subject to multiple conditions and approvals
- Integration risks with existing operations
- Revenue milestone of US$25M required for share payment may not be achieved
Strategic Acquisition Bolsters AI-Driven Healthcare Innovation, Positioning Fifty 1 Labs as a Leader in Clinical Data Analytics
VANCOUVER, British Columbia, Sept. 30, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty 1 Labs Inc. (OTC: FITY), a leader in AI-powered healthcare and biotechnology solutions, is excited to announce the signing of a Letter of Intent (LOI) to acquire BioSpark AI Technologies Inc., a Vancouver-based innovator specializing in patented artificial intelligence systems for clinical data extraction, structuring, and real-time analysis. This strategic move builds on a successful history of collaboration between the two companies, reinforcing Fifty 1 Labs' commitment to advancing therapeutic development and functional medicine through cutting-edge AI technology.
The LOI outlines Fifty 1 Labs' intent to acquire
Fifty 1 Labs and BioSpark have a proven track record of collaboration. As previously announced on OTC Markets, their strategic partnership through Fifty 1 Labs' subsidiary, Fifty1 AI Labs, has driven breakthroughs in drug repurposing by leveraging BioSpark's advanced AI tools to identify new therapeutic applications for existing compounds. Most recently, this collaboration unlocked over 2,000 real-world treatment pathways, accelerating innovation in functional medicine by processing clinical narratives with unmatched efficiency. These achievements underscore the transformative potential of BioSpark's technology and its alignment with Fifty 1 Labs' vision for AI-driven healthcare innovation.
"This Letter of Intent represents a pivotal step toward redefining healthcare through artificial intelligence," said Paul Arora, Chief Executive Officer of Fifty 1 Labs Inc. "Our successful collaborations with BioSpark have demonstrated the power of their AI systems in advancing drug discovery and clinical insights. By pursuing this acquisition, we aim to fully integrate BioSpark's capabilities, positioning Fifty 1 Labs as a global leader in the rapidly growing AI-healthcare market. This move reflects our dedication to delivering innovative solutions that improve patient outcomes and create significant shareholder value."
The LOI includes an exclusivity period to facilitate negotiations toward a definitive Stock Purchase Agreement, with closing subject to completion of due diligence, negotiation and execution of the Definitive Agreement, board approvals, regulatory approvals or filings under applicable securities laws, certification of the revenue-based milestone, no material adverse change in the business of either party, and other customary conditions. Fifty 1 Labs intends to retain key BioSpark employees post-closing on substantially similar terms, at its discretion, to ensure continuity and leverage their expertise for future growth. This acquisition positions Fifty 1 Labs to capitalize on the increasing demand for AI-driven clinical data solutions, targeting opportunities in the multi-billion-dollar markets of drug repurposing, personalized medicine, and healthcare optimization.
About BioSpark AI Technologies Inc.
Founded in Vancouver, BioSpark AI Technologies Inc. is engaged in developing, marketing, and commercializing patented artificial intelligence systems for clinical data extraction, structuring, and analysis. Its proprietary large language model (LLM) ensemble technology enables real-time mining and processing of clinical narratives for therapeutic development, outcomes research, and related applications. For more information, visit https://www.biospark.ai.
About Fifty1 AI Labs
Fifty1 AI Labs, a subsidiary of Fifty 1 Labs, Inc. (OTC: FITY), is redefining drug discovery by using AI to unlock new potential in proven medicines. By repurposing safe, off-patent compounds, we accelerate smarter therapies that improve lives, reduce costs, and create lasting value for patients, partners, and forward-thinking investors.
Contact:
Investor Relations
Fifty 1 Labs, Inc.
ir@fifty1labs.com | (877) 505-5006
www.fifty1AIlabs.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release, including statements regarding the potential impact, development, and timeline of AI-powered drug repurposing, the proposed acquisition of BioSpark AI Technologies Inc., and the ability of Fifty 1 Labs' platform to transform clinical data analytics and global health outcomes, are forward-looking statements. These statements involve known and unknown risks, uncertainties, and other important factors that may cause the company's actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. These risks and uncertainties include, but are not limited to, the success and timing of the proposed acquisition, achievement of the revenue-based valuation milestone, regulatory approvals, and the company's ability to successfully integrate and commercialize BioSpark's technologies. For a further description of the risks and uncertainties, please refer to Fifty 1 Labs, Inc.'s filings with the OTC Markets. The company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
FAQ
What are the terms of Fifty 1 Labs (FITY) acquisition of BioSpark AI Technologies?
How will the BioSpark acquisition benefit Fifty 1 Labs (FITY)?
What previous successes have Fifty 1 Labs and BioSpark achieved together?
What conditions must be met for the Fifty 1 Labs-BioSpark deal to close?
How will the acquisition impact FITY shareholders?
